Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) rose 18.2% on Tuesday . The company traded as high as C$1.69 and last traded at C$1.62. Approximately 747,191 shares changed hands during trading, an increase of 455% from the average daily volume of 134,529 shares. The stock had previously closed at C$1.37.
Wall Street Analyst Weigh In
Separately, Jones Trading downgraded Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.
Read Our Latest Research Report on ONC
Oncolytics Biotech Trading Down 5.3%
The stock has a market capitalization of C$124.09 million, a PE ratio of -4.49 and a beta of 1.35. The stock's 50 day moving average price is C$0.78 and its 200-day moving average price is C$0.93. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
